Frederic Triebel

Frederic Triebel

Company: Immutep

Job title: Chief Scientific Officer & Chief Medical Officer

Seminars:

A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC 12:00 pm

An MHC class II agonist (eftilagimod) used as an antigen presenting cell (APC) activator combined with an immune checkpoint inhibitor (ICI) Results in first (114 patients) and second (36 PD-X refractory patients) lines NSCLC A systemic APC activator injected s.c. plus an ICI: a potent combination for PDL-1 unselected patientsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.